Skip to main content

KNSA Kiniksa Pharmaceuticals International, plc

Healthcare

88.34 USD 1D -7.78 -8.09% Close 11/5
Since 2024-12-05 +358.2%

Close 11/5

Open
95.49
High
96.99
Low
87.30
Prev close
96.12
Volume
960.62K
Amplitude
10.08%
P/E
73.4
P/B
10.6
Revenue YoY (TTM)
+58.2%
52W 37.02 98.48
FinLab Studio

From Kiniksa Pharmaceuticals International, plc to every stock like it

AI finds several complementary traits of Kiniksa Pharmaceuticals International, plc across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Kiniksa Pharmaceuticals International, plc

Is Kiniksa Pharmaceuticals International, plc a buy? Fundamentals and valuation first

As of 2026-11-04

Quality: Good, Growth: Strong, Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 73.4 89th percentile · Expensive
Price / book 10.6 92th percentile · Expensive
Free-cash-flow yield (%) 2.6 57th percentile · Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good All 3 indicators are Good.
ROE, TTM (%) 15.4 77th percentile · Good
Operating margin, TTM (%) 13.8 62th percentile · Good
FCF margin, TTM (%) 20.9 77th percentile · Good
Quality Factor Investing: A US Quality Value Backtest
Growth Strong All 2 indicators are Top.
Revenue growth, TTM YoY (%) 58.2 88th percentile · Top
Diluted EPS growth, TTM YoY (%) 191.1 89th percentile · Top
Momentum Strong All 2 indicators are Top.
60-day return (%) 23.6 94th percentile · Top
240-day return (%) 128.0 97th percentile · Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 81,739,892.0 85th percentile · Top
60-day annualized volatility (%) 58.0 62th percentile · Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Kiniksa Pharmaceuticals International, plc (KNSA) today

3 quant signals active · As of 2026-11-04

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Kiniksa Pharmaceuticals International, plc (KNSA) peers and tracking

Watchlist

This page refreshes daily after the close. Add Kiniksa Pharmaceuticals International, plc to your watchlist to track signal changes on your next visit.

Kiniksa Pharmaceuticals International, plc (KNSA) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

18 historical occurrences (since 2020-04-21)

Average forward return after 52-week adjusted-price high

20-day: Win 41.2%, Sample 17, Median -1.4%, Excess -2.7%, Beat mkt rate 23.5%

60-day: Win 70.6%, Sample 17, Median +8.2%, Excess -0.4%, Beat mkt rate 47.1%

120-day: Win 66.7%, Sample 15, Median +23.8%, Excess +9.0%, Beat mkt rate 60.0%

120 days after: historical avg +18.9%

20-day -0.5%
60-day +5.0%
120-day +18.9%
20-day
60-day
120-day
Win
41.2%
70.6%
66.7%
Sample
17
17
15
Median
-1.4%
+8.2%
+23.8%
Excess
-2.7%
-0.4%
+9.0%
Beat mkt rate
23.5%
47.1%
60.0%

Over 15 occurrences, 120-day forward avg gained 18.9%, beat the market by 9.0 pts; win rate 66.7%.

Top-quintile 6-month momentum

Active · now 95.2%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
19 historical occurrences (since 2018-11-26)

Average forward return after Top-quintile 6-month momentum

20-day: Win 57.9%, Sample 19, Median +1.0%, Excess -0.2%, Beat mkt rate 47.4%

60-day: Win 63.2%, Sample 19, Median +8.7%, Excess +1.0%, Beat mkt rate 47.4%

120-day: Win 66.7%, Sample 18, Median +18.2%, Excess +7.4%, Beat mkt rate 55.6%

120 days after: historical avg +16.4%

20-day +1.0%
60-day +4.0%
120-day +16.4%
20-day
60-day
120-day
Win
57.9%
63.2%
66.7%
Sample
19
19
18
Median
+1.0%
+8.7%
+18.2%
Excess
-0.2%
+1.0%
+7.4%
Beat mkt rate
47.4%
47.4%
55.6%

Over 18 occurrences, 120-day forward avg gained 16.4%, beat the market by 7.4 pts; win rate 66.7%.

EPS surprise beat

Active · now 50.9%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
16 historical occurrences (since 2019-08-12)

Average forward return after EPS surprise beat

20-day: Win 40.0%, Sample 15, Median -1.8%, Excess +1.5%, Beat mkt rate 26.7%

60-day: Win 53.3%, Sample 15, Median +0.1%, Excess +4.2%, Beat mkt rate 40.0%

120-day: Win 60.0%, Sample 15, Median +29.3%, Excess +22.5%, Beat mkt rate 60.0%

120 days after: historical avg +27.6%

20-day +3.3%
60-day +7.6%
120-day +27.6%
20-day
60-day
120-day
Win
40.0%
53.3%
60.0%
Sample
15
15
15
Median
-1.8%
+0.1%
+29.3%
Excess
+1.5%
+4.2%
+22.5%
Beat mkt rate
26.7%
40.0%
60.0%

Over 15 occurrences, 120-day forward avg gained 27.6%, beat the market by 22.5 pts; win rate 60.0%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 100,217 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.37%, a 58.3% positive-return rate, and +3.03 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

6 times historically; 60-day forward avg +15.9%, win rate 83.3%, beating the market by +9.3 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.